# A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

> **NCT04736394** · PHASE3 · UNKNOWN · sponsor: **Jiangsu Yahong Meditech Co., Ltd aka Asieris** · enrollment: 800 (estimated)

## Conditions studied

- Non-muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** APL-1202
- **DRUG:** Epirubicin Hydrochloride

## Key facts

- **NCT ID:** NCT04736394
- **Lead sponsor:** Jiangsu Yahong Meditech Co., Ltd aka Asieris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-29
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04736394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04736394, "A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04736394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*